Citation
Kraft, Letícia, et al. "Comparison of Amphotericin B Lipid Complex, Deoxycholate Amphotericin B, Fluconazole, and Anidulafungin Activity Against Candida Albicans Biofilm Isolated From Breakthrough Candidemia." Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.), 2023.
Kraft L, Ribeiro VST, Gonçalves GA, et al. Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia. Enferm Infecc Microbiol Clin (Engl Ed). 2023.
Kraft, L., Ribeiro, V. S. T., Gonçalves, G. A., Suss, P. H., & Tuon, F. F. (2023). Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.). https://doi.org/10.1016/j.eimce.2022.07.009
Kraft L, et al. Comparison of Amphotericin B Lipid Complex, Deoxycholate Amphotericin B, Fluconazole, and Anidulafungin Activity Against Candida Albicans Biofilm Isolated From Breakthrough Candidemia. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jan 25; PubMed PMID: 36707288.
TY - JOUR
T1 - Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia.
AU - Kraft,Letícia,
AU - Ribeiro,Victoria Stadler Tasca,
AU - Gonçalves,Geiziane Aparecida,
AU - Suss,Paula Hansen,
AU - Tuon,Felipe Francisco,
Y1 - 2023/01/25/
PY - 2022/04/20/received
PY - 2022/07/19/accepted
PY - 2023/1/27/entrez
PY - 2023/1/28/pubmed
PY - 2023/1/28/medline
KW - Antifungals
KW - Antifúngico
KW - Biofilms
KW - Breakthrough candidemia
KW - Candida
KW - Candidemia
KW - Candidemia de brecha
JF - Enfermedades infecciosas y microbiologia clinica (English ed.)
JO - Enferm Infecc Microbiol Clin (Engl Ed)
N2 - INTRODUCTION: Biofilm formation causes virulence and resistance in Candida albicans. However, little is known about breakthrough candidemia isolates. We evaluated the antifungal activity of fluconazole, anidulafungin, deoxycholate amphotericin B (dAMB), and amphotericin B lipid complex (ABLC) against biofilms of C. albicans isolated from patients with breakthrough candidemia. METHODS: The present study used strains of C. albicans isolated from breakthrough and non-breakthrough candidemia patients (control group). The susceptibility of planktonic cells to amphotericin B, anidulafungin, and fluconazole was determined by broth microdilution. Antifungal activity in sessile cells was evaluated using the minimum biofilm eradication concentration (MBEC), metabolic activity was estimated by reducing MTT, and biomass was estimated using crystal violet retention. RESULTS: The planktonic strains were susceptible to amphotericin B, anidulafungin, and fluconazole, with minimum inhibitory concentrations of 1, ≤0.03, and 2mg/L, respectively. However, fluconazole and anidulafungin did not exert an antifungal effect on biofilms. Additionally, dAMB and ABCL reduced the metabolic activity and biomass. However, eradication was only achieved using 16mg/L dAMB. C. albicans isolates of breakthrough candidemia exhibited strong biofilm production, and the in vitro activity of available therapeutic options was poor. CONCLUSION: In the present study, only dAMB and ABCL exhibited antibiofilm effects against sessile breakthrough candidemia isolates.
SN - 2529-993X
UR - https://www.unboundmedicine.com/medline/citation/36707288/Comparison_of_amphotericin_B_lipid_complex,_deoxycholate_amphotericin_B,_fluconazole,_and_anidulafungin_activity_against_Candida_albicans_biofilm_isolated_from_breakthrough_candidemia.
DB - PRIME
DP - Unbound Medicine
ER -